Literature DB >> 18511806

CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor.

Hedwich F Kuipers1, Paula J Biesta, Lisette J Montagne, Elise S van Haastert, Paul van der Valk, Peter J van den Elsen.   

Abstract

The chemokine receptor CCR5 is implicated in the pathogenesis of various inflammatory diseases, such as multiple sclerosis (MS), atherosclerosis, transplant rejection, and autoimmunity. In previous studies, we have shown that MS lesions are characterized by enhanced expression of transcription factors associated with stress responses, ie, IRF-1, NF-kappaB, and CREB-1, which modulate expression of both classes of major histocompatibility complex (MHC) molecules. The expression of MHC-I and MHC-II molecules greatly overlaps with the expression of CCR5 in MS lesions. Therefore, we investigated whether these factors are also involved in the transcriptional regulation of CCR5. Using in vitro assays, we determined that neither IRF-1 nor NF-kappaB is involved in the activation of the CCR5 promoter. This is corroborated by the finding that these factors are not involved in the induction of endogenous CCR5 transcription in various cell types. In contrast, we show that CCR5 expression is regulated by the cAMP/CREB pathway and that interference in this pathway affects endogenous CCR5 transcription. From this, we conclude that the cAMP/CREB pathway is involved in the regulation of CCR5 transcription and that, given the ubiquitous nature of CREB-1 protein expression, additional regulatory mechanisms must contribute to cell type-specific expression of CCR5.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511806     DOI: 10.1182/blood-2008-01-135111

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Transcriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathway.

Authors:  Anupam Banerjee; Vanessa Pirrone; Brian Wigdahl; Michael R Nonnemacher
Journal:  Biomed Pharmacother       Date:  2011-05-30       Impact factor: 6.529

Review 2.  Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis.

Authors:  Anupam Banerjee; Marianne Strazza; Brian Wigdahl; Vanessa Pirrone; Olimpia Meucci; Michael R Nonnemacher
Journal:  J Neurovirol       Date:  2011-07-07       Impact factor: 2.643

3.  CCR5 promoter haplotype transcription complex characterization.

Authors:  Daifeng Jiang; Srinivas Mummidi; Sunil K Ahuja; Harry W Jarrett
Journal:  J Health Care Poor Underserved       Date:  2011

4.  Tumor progression locus 2 (Tpl2) kinase promotes chemokine receptor expression and macrophage migration during acute inflammation.

Authors:  Sean M Rowley; Teneema Kuriakose; Lee M Dockery; Thi Tran-Nguyen; Aaron D Gingerich; Lai Wei; Wendy T Watford
Journal:  J Biol Chem       Date:  2014-04-08       Impact factor: 5.157

Review 5.  Is the CCR5 Δ 32 mutation associated with immune system-related diseases?

Authors:  Khodayar Ghorban; Maryam Dadmanesh; Gholamhossein Hassanshahi; Mohammad Momeni; Mohammad Zare-Bidaki; Mohammad Kazemi Arababadi; Derek Kennedy
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

6.  A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Authors:  Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

7.  Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection.

Authors:  Max W Richardson; Julie Jadlowsky; Chuka A Didigu; Robert W Doms; James L Riley
Journal:  J Immunol       Date:  2012-09-17       Impact factor: 5.422

8.  Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor.

Authors:  German G Gornalusse; Srinivas Mummidi; Alvaro A Gaitan; Fabio Jimenez; Veron Ramsuran; Anabela Picton; Kristen Rogers; Muthu Saravanan Manoharan; Nymisha Avadhanam; Krishna K Murthy; Hernan Martinez; Angela Molano Murillo; Zoya A Chykarenko; Richard Hutt; Demetre Daskalakis; Ludmila Shostakovich-Koretskaya; Salim Abdool Karim; Jeffrey N Martin; Steven G Deeks; Frederick Hecht; Elizabeth Sinclair; Robert A Clark; Jason Okulicz; Fred T Valentine; Neil Martinson; Caroline Tanya Tiemessen; Thumbi Ndung'u; Peter W Hunt; Weijing He; Sunil K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-11       Impact factor: 11.205

9.  The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation.

Authors:  Gero Hütter; Martin Neumann; Daniel Nowak; Stefan Klein; Harald Klüter; Wolf-K Hofmann
Journal:  J Inflamm (Lond)       Date:  2011-10-26       Impact factor: 4.981

10.  Epigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitors.

Authors:  Rutger J Wierda; Hedwich F Kuipers; Marja C J A van Eggermond; Anne Benard; Jan C van Leeuwen; Silvia Carluccio; Sacha B Geutskens; J Wouter Jukema; Victor E Marquez; Paul H A Quax; Peter J van den Elsen
Journal:  J Cell Mol Med       Date:  2012-08       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.